MetaCap

ANI Pharmaceuticals (ANIP) vs Braveheart Bio (BRVE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Braveheart Bio is the larger company by market cap ($1.67 billion vs $1.56 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANIP-17.04%BRVE-31.58%
+3%-20%-44%
Aug 6, 20261 yearNov 20, 2026
ANIP-12.40%BRVE-32.03%
+2%-19%-40%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANIP versus BRVE key metrics
MetricANIPBRVE
Share price$68.55$20.39
Market cap$1.56B$1.67B
1-day change-0.84%+5.81%
YTD return-13.16%—
1-year return-14.01%—
5-year return+68.14%—
P/E ratio (TTM)13.90—
Forward P/E6.72—
EPS (TTM)$4.93$-6.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$883.37M—
Revenue growth (YoY)+43.78%—
Net income (latest FY)$78.34M—
Gross margin61.36%—
Operating margin12.58%—
Net margin8.87%—
52-week high$87.76$32.00
52-week low$67.14$16.70
Distance from 52-week high-21.89%-36.28%
Analyst consensusbuystrong_buy
Avg. price target upside+50.81%+123.15%
Average volume420.66K491.27K
Shares outstanding22.72M82.07M
Employees97049
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About ANI Pharmaceuticals

ANIP stock →

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.

Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees

About Braveheart Bio

BRVE stock →

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

ANIP vs BRVE FAQ

Which is bigger, ANI Pharmaceuticals or Braveheart Bio?

Braveheart Bio (BRVE) is larger, with a market capitalization of $1.67B compared with $1.56B for ANI Pharmaceuticals (ANIP).

Are ANI Pharmaceuticals and Braveheart Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons